Tip 2 diyabet hastalarında glikolize hemoglobin ve plataletcrit ilişkisi

Amaç: Tip 2 diyabet ciddi damar hastalıklarına yol açabilen bir hastalıktır. Plateletcrit (PCT) anormal düzeyleri yapılan çalışmalarda koroner arter hastalıkları için risk faktörü olarak belirlenmiştir. Glikolize hemoglobin (HbA1c), glisemik kontrolü değerlendirmek için geniş kullanıma sahip bir belirteçtir. Bu çalışmada PCT ile HbA1c arasındaki ilişkinin değerlendirilmesi amaçlanmıştır.Gereç ve yöntem: Çalışma, retrospektif vaka kontrol çalışmasıdır. Tip 2 diyabetli 65 hastanın geçmiş kayıtları değerlendirilmiş,HbA1c ve MPV, PCT arasındaki ilişki araştırılmıştır.Bulgular: HbA1c ve PCT arasında anlamlı korelasyon saptandı (r=0,4 p<0,01). MPV ile korelasyon saptanmadı. Sonuç: PCT, glisemik kontrolü sağlanmayan ve buna bağlı vasküler hasar gelişme olasılığı olan hastalarda yol gösterici olabilir. Bu açıdan, anormal PCT düzeyleri olan hastaların vasküler patolojiler açısından yakın takibi önemli olabilir.

Anahtar Kelimeler:

HbA1c, plataletcrit, glisemik kontrol, tip 2 diyabet

Relationship between glycosylated hemoglobin and plateletcrit of type 2 diabetes patients

Aim: Type 2 diabetes can cause serious vascular problems. Abnormal plateletcrit (PCT) levels were shown as a risc factor for coronary artery diseases by recent studies. Glycosylated hemoglonin (HbA1c) is widely ysed marker for assessment of glycemic control. This study aimed to evaluate relationship between HbA1c and PCT.Material and Method: It is retrospective case control study. 65 type 2 diabetic patients’ records were evaluated. Correlation between HbA1c and PCT, MPV was investigated.Results: Between HbA1c and PCT levels, statistically significant correlation was detected (r=0,4 p<0,01). Any correlation wasn’t detected with MPV. Conclusion: Plateletcrit may be guide for preventing vascular complication due to poor glycemic regulation. Therefore patients with increased plateletcrit values, should be evaluated for higher risk of vascular complications.

Keywords:

HbA1c, glycemic control, plataletcrit, type 2 diabetes,

PDF

___

1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with Type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005; 54: 2430-5.
2. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, et al. Erratum: Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA Diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association (Diabetes Care (2009) 32 (187-192)). Diabetes Care [Internet]. 2009;32(4):754. Available from: http://dx.doi.org/10.1016/j.jacc.2008.10.008
3. Ergelen M, Uyarel H. Plateletcrit: A novel prognostic marker for acute coronary syndrome. Int J Cardiol [Internet]. 2014;177(1):161. Available from: http://dx.doi.org/10.1016/j.ijcard.2014.09.054
4. Uğur M, Ayhan E, Bozbay M, Çiçek G, Ergelen M, Işik T, et al. The independent association of plateletcrit with long-term outcomes in patients undergoing primary percutaneous coronary intervention. J Crit Care. 2014;29(6):978–81.
5. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiol- ogy of type 2 diabetes mellitus-present and future perspec- tives. Nat Rev Endocrinol 2012; 8(4): 228.
6. Liu J, Liu X, Li Y, et al. The association of neutrophil to lymphocyte ratio, mean platelet volume, and platelet distribution width with diabetic retinopathy and nephropathy: a meta-analysis. Biosci Rep [Internet]. 2018;38(3):BSR20180172. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29581246
7. Rechcinski T, Jasinska A, Forys J, et al. Prognostic value of platelet indices after acute myocardial infarction treated with primary percutaneous coronary intervention. Cardiol J 2013; 20: 491-8
8. Jaman S. Association of Mean Platelet Volume and Platelet Distribution Width with Hba1c. J Endocrinol Diabetes [Internet]. 2017; 4 : 1–6.
9. Tvedten H, Lilliehöök I, Hillström A, Häggström J. Plateletcritis superior to platelet count for assessing platelet status in Cavalier King Charles Spaniels. Vet Clin Pathol; 37: 266–271
10. Yazgan S, Celik U, Ayar O, et al. The role of patient’s systemic characteristics and plateletcrit in developing toxic anterior segment syndrome after uneventful phaco surgery: A case–control study. Int Ophthalmol. 2018; 38: 43–52.
11. Alhadas KR, Santos SN, Mara Freitas MS, et al. Are platelet indices useful in the evaluation of type 2 diabetic patients? Os índices plaquetários são úteis na avaliação de pacientes diabéticos tipo 2? J Bras Patol Med Lab [Internet]. 2016; 52 :105–11.
12. Anandhalakshmi S, Kalaivani A, Shivashekar G, Saravanan A. Evaluation of mean platelet volume and other platelet parameters in subjects with Type-2 diabetes mellitus. Natl J Physiol Pharm Pharmacol. 2017; 7: 51–4.
13. Atak BM, Duman TT, Aktas G, Kocak MZ, Savli H. Platelet Distribution Width is Associated with Type 2 Diabetes Mellitus and Diabetic Nephropathy and Neuropathy. 2018; 95–8.
14. Havakuk O, Banai S, Halkin A, et al. HbA1cLevels and Long-Term Mortality in Patients Undergoing Coronary Angiography. Cardiol. 2016; 134: 101–6.
15. Schoos MM, Dangas GD, Mehran R, et al. Impact of hemoglobin a1c levels on residual platelet reactivity and outcomes after insertion of coronary drug-eluting stents (from the ADAPT-DES Study). Am J Cardiol [Internet]. 2016; 117: 192–200.